Clinical trials: Spondylarthropathy
Arthritis, Psoriatic
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and…
- Trial name
- NCT01490450
- Testing
- BMS-945429
- Where
- 49 sites in United States, Argentina and 11 more
- Volunteers
- 165 people
- Sponsor
- CSL Behring
Spondyloarthritis
SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
The purpose of the study was to evaluate the efficacy and safety of secukinumab 150 mg compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease activity, fatigue, and predictability of disease…
- Trial name
- SKIPPAIN (NCT03136861)
- Testing
- AIN457
- Where
- 66 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Spondyloarthritis
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).
- Trial name
- COAST-W (NCT02696798)
- Testing
- Ixekizumab
- Where
- 99 sites in United States, Argentina and 15 more
- Volunteers
- 316 people
- Sponsor
- Eli Lilly and Company
Axial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
The purpose of this study is to assess the efficacy of ustekinumab, in adult participants with active radiographic axial spondyloarthritis (AxSpA), who are naive to anti-TNF alpha agents, as measured by the reduction in signs and…
- Trial name
- NCT02437162
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Where
- 57 sites in United States, Czechia and 5 more
- Volunteers
- 347 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are…
- Trial name
- EXCEED 1 (NCT02745080)
- Testing
- Secukinumab, Adalimumab
- Where
- 156 sites in United States, Australia and 24 more
- Volunteers
- 853 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal…
- Trial name
- NCT01114880
- Testing
- adalimumab
- Where
- 9 sites in China
- Volunteers
- 344 people
- Sponsor
- Abbott
Ankylosing Spondylitis (AS)
BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
The overall purpose of the trial is to assess the clinical efficacy of three different subcutaneous doses of BI 655066 (risankizumab) in adult patients with AS, in order to provide clinical proof of concept and to select dose (s)…
- Trial name
- NCT02047110
- Testing
- risankizumab
- Volunteers
- 159 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
The purpose of this study is to assess the ability of people with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) to use an experimental autoinjector to self inject etanercept (Enbrel®).
- Trial name
- NCT01901185
- Testing
- Etanercept / Autoinjector A
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Amgen
Spondyloarthropathies
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of Certolizumab Pegol (CZP) in subjects with active axial Spondyloarthritis (axial…
- Trial name
- NCT01087762
- Testing
- CZP 200 mg Q2W, CZP 400 mg Q4W
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 325 people
- Sponsor
- UCB BIOSCIENCES GmbH
Psoriatic Arthritis
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA…
- Trial name
- FUTURE 2 (NCT01752634)
- Testing
- Secukinumab (AIN457)
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
AMG 827 in Subjects With Psoriatic Arthritis
The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis
- Trial name
- NCT01516957
- Testing
- AMG 827 140, AMG 827 280, AMG 827 210
- Where
- 31 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Bausch Health Americas, Inc.
Ankylosing Spondylitis
Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis
The purpose of this study was to assess the clinical efficacy, safety and tolerability of secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS despite current or previous non-steroidal…
- Trial name
- NCT02750592
- Testing
- Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
- Where
- 10 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)
This study is to evaluate the local data in Iraqi patients with psoriatic arthritis on Enbrel treatment with positive Anti-Cyclic Citrullinated Peptide using data from the Rheumatologist in Baghdad Teaching Hospital registry.
- Trial name
- NCT04428502
- Testing
- Enbrel
- Where
- Iraq
- Volunteers
- 127 people
- Sponsor
- Pfizer
Ankylosing Spondylitis, Axial Spondyloarthritis
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
The primary objective of this study was to assess the proportion of participants in the infliximab plus naproxen arm versus the placebo plus naproxen arm, in a population of participants with moderate-to-severe active axial…
- Trial name
- INFAST (NCT00844805)
- Testing
- Infliximab, Naproxen
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Ankylosing Spondylitis
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active ankylosing spondylitis (chronic…
- Trial name
- NCT02186873
- Testing
- Golimumab
- Where
- 45 sites in United States, Australia and 7 more
- Volunteers
- 208 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis
This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).
- Trial name
- NCT05153148
- Testing
- NDI-034858
- Where
- 56 sites in United States, Czechia and 2 more
- Volunteers
- 305 people
- Sponsor
- Takeda
Psoriatic Arthritis
A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis
This study is designed to assess the efficacy of apremilast, either in monotherapy or with stable methotrexate, on imaging outcomes in adults with active psoriatic arthritis with less than 5 years of disease duration (since…
- Trial name
- MOSAIC (NCT03783026)
- Testing
- Apremilast
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 123 people
- Sponsor
- Amgen
Spondylitis, Ankylosing, SpA
Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)
Subjects will be given 3 infusions of infliximab according to the label at week 0, 2, and 6. Subjects will be followed for a maximum of 18 weeks or until relapse.
- Trial name
- EUSpA (NCT00686894)
- Testing
- PDUS, Infliximab
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
Axial Spondyloarthritis
A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)
This study is a non-interventional, longitudinal and non-confirmatory study to compare an active supervised training (AST) with standard of care (SOC) physiotherapy in patients with axial spondyloarthritis and stable response to…
- Trial name
- Treat & Train (NCT03258814)
- Testing
- Active Supervised Training (AST), Standard of Care (SOC) Physiotherapy
- Where
- 6 sites in Germany
- Volunteers
- 17 people
- Sponsor
- AbbVie
Spondylitis, Ankylosing
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
The purpose of this study is to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and…
- Trial name
- MEASURE4 (NCT02159053)
- Testing
- Secukinumab
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 350 people
- Sponsor
- Novartis Pharmaceuticals